Zinc as a marker of cancer risk

Katarzyna Białkowska1*, Wojciech Marciniak2, Róża Derka2, Magdalena Muszyńska2, Grzegorz Sukiennicki1, Marcin Lener1, Katarzyna Durda1, Katarzyna Jaworska-Bieniek1, Alicja Łukomska1, Karolina Prążzendanc1, Tomasz Huzarski3, Tomasz Byrski1, Oleg Oszurek1, Cezary Cybulski1, Tadeusz Dębiak1, Antoni Morawski2, Anna Jakubowska3, Jan Lubiński1,2

1Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
2Read – Gene, S.A., Grzepnica, Poland
3Independent laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland

Background
Zinc is a micronutrient, which is essential for human health, involved in regulation of gene expression, e.g. genes related to cell cycle, apoptosis, response to DNA damage, antioxidant defense, immune response. Literature data on zinc association with cancer risk show inconclusive results.

Aim of the study
The aim of the study was to evaluate the relationship between zinc blood levels and subsequent cancer risk in a large prospective cohort of persons followed for incident cases of cancer in Szczecin Poland.

Material and methods
The study was conducted in 3 prospective cohort consisted of persons with no cancer at that baseline:
1. 601 women with BRCA1 mutation, among them 42 cancers were identified during the follow-up
2. 1698 women without BRCA1 mutation, among them 110 cancers were identified during the follow-up
3. 1467 men, among them 42 cancers were identified during the follow-up.

Zinc level blood was measured by inductively coupled plasma mass spectrometry (ICP-MS) using Elan DRC-e ICP-Mass Spectrometer, Perkin Elmer. Odds Ratios were calculated using Fisher’s exact test.

Results
It was observed that female BRCA1 mutation carriers with Zn blood level 6300 – 6700 μg/L have 4-fold lower risk than carriers with Zn level <6300 μg/L or >6700 μg/L (regardless to age) (OR=0.24; 95%CI 0.06 – 1; p=0.03). Results from the cohort of women without BRCA1 mutation and cohort of men revealed that Zn blood level at which cancer risk is decreased is strongly dependent on age. Women <60 y/o with Zn blood level >6800 μg/L have 3-fold lower risk than women with Zn level <6800 μg/L (OR=0.3; 95%CI 0.09 – 0.97; p=0.04). For women >60 y/o a tendency to 3-fold reduced risk is observed with Zn blood level 5600 – 6000 μg/L comparing to Zn level <5600 or >6000 μg/L (OR=0.3; 95%CI 0.1 – 1.1; p=0.06).

In the cohort of men individuals <60 y/o and Zn blood level 6300 - 6800 μg/L have 3-fold lower risk of cancer than men with Zn level <6300 μg/L or > 6800 μg/L (OR=0.31; 95% CI 0,11 – 0,89; p=0.02). Men >60 y/o and Zn blood level 7000 – 7300 μg/L have 10-fold lower risk of cancer than men with Zn level <7000 μg/L or >7300 μg/L (OR=0.1; 95% CI 0.01 – 0.72; p=0.003).

Conclusions
Results from this study suggest that blood zinc level is a strong marker of cancer risk. It might be a subject of future studies to establish whether zinc intake modifications changing Zn blood level will be an effective way of cancer prevention.